Maegim한국어

환인제약

016580KOSPISector: Pharma & Biotech
₩9,830▼ 0.91%Market cap ₩182.8BAs of Jul 21, 2026 close · updated once daily
A
Grade A68.3 ptsTop 15% of 2,523 stocks
Financial strength
73.0
Growth momentum
35.3
Price attractiveness
86.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

73.0
How much debt does it carry relative to equity?
Debt-to-equity ratio
13.7%
✓ Above median · Top 15.2% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
404.0%
✓ Above median · Top 30.3% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
5.1%
✓ Above median · Top 29% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
3.2%
✓ Above median · Top 33.5% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

35.3
How much did revenue grow in a year?
Revenue growth (YoY)
-1.7%
✗ Below median · Top 71% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
8.7%
✓ Above median · Top 36% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-39.4%
✗ Below median · Top 79.2% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-56.3%
✗ Below median · Top 72.8% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

86.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
13.4x
✓ Above median · Top 19.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.43x
✓ Above median · Top 7.9% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15